Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guilherme Baldo

Showing results (1-10 of 105) with videos related to

Pageof 11
Sort By:
Molecular Therapy. Methods & Clinical Development|August 28, 2023
Crossing the gates of Babylon: Brain-penetrating enzyme replacement for lysosomal disordersGuilherme Baldo
Nature Medicine|August 19, 2025
Location matters for brain gene therapy in lysosomal disordersGuilherme Baldo
Progress in Molecular Biology and Translational Science|June 15, 2021
Creating cell lines for mimicking diseasesEdina Poletto, Guilherme Baldo
Expert Opinion on Investigational Drugs|October 26, 2017
Phase I and II clinical trials for the mucopolysaccharidosesFabiano Poswar, Guilherme Baldo, Roberto Giugliani
Medical Hypotheses|February 25, 2014
Lysosomal enzymes may cross the blood-brain-barrier by pinocytosis: implications for enzyme replacement therapyGuilherme Baldo, Roberto Giugliani, Ursula Matte
BMC Medical Genetics|October 6, 2018
Comment on "report of 5 novel mutations of the α-L-iduronidase gene and comparison of Korean mutations in relation with those of Japan or China in patients with mucopolysaccharidosis I"Edina Poletto, Ursula Matte, Guilherme Baldo
Expert Opinion on Drug Delivery|January 24, 2014
Gene delivery strategies for the treatment of mucopolysaccharidosesGuilherme Baldo, Roberto Giugliani, Ursula Matte
International Journal of Molecular Sciences|January 17, 2020
Genome Editing for MucopolysaccharidosesEdina Poletto, Guilherme Baldo, Natalia Gomez-Ospina
Expert Opinion on Drug Delivery|June 21, 2016
Nanotechnology applied to treatment of mucopolysaccharidosesRoselena S Schuh, Guilherme Baldo, Helder F Teixeira
Frontiers in Genome Editing|July 24, 2023
Editorial: <i>Ex-vivo</i> and <i>in-vivo</i> genome engineering for metabolic and neurometabolic diseasesPasqualina Colella, Vasco Meneghini, Guilherme Baldo, et al.
Pageof 11

Showing results (1-10 of 105) with videos related to

Sort By:
Pageof 11
Molecular Therapy. Methods & Clinical Development|August 28, 2023
Crossing the gates of Babylon: Brain-penetrating enzyme replacement for lysosomal disordersGuilherme Baldo
Nature Medicine|August 19, 2025
Location matters for brain gene therapy in lysosomal disordersGuilherme Baldo
Progress in Molecular Biology and Translational Science|June 15, 2021
Creating cell lines for mimicking diseasesEdina Poletto, Guilherme Baldo
Expert Opinion on Investigational Drugs|October 26, 2017
Phase I and II clinical trials for the mucopolysaccharidosesFabiano Poswar, Guilherme Baldo, Roberto Giugliani
Medical Hypotheses|February 25, 2014
Lysosomal enzymes may cross the blood-brain-barrier by pinocytosis: implications for enzyme replacement therapyGuilherme Baldo, Roberto Giugliani, Ursula Matte
BMC Medical Genetics|October 6, 2018
Comment on "report of 5 novel mutations of the α-L-iduronidase gene and comparison of Korean mutations in relation with those of Japan or China in patients with mucopolysaccharidosis I"Edina Poletto, Ursula Matte, Guilherme Baldo
Expert Opinion on Drug Delivery|January 24, 2014
Gene delivery strategies for the treatment of mucopolysaccharidosesGuilherme Baldo, Roberto Giugliani, Ursula Matte
International Journal of Molecular Sciences|January 17, 2020
Genome Editing for MucopolysaccharidosesEdina Poletto, Guilherme Baldo, Natalia Gomez-Ospina
Expert Opinion on Drug Delivery|June 21, 2016
Nanotechnology applied to treatment of mucopolysaccharidosesRoselena S Schuh, Guilherme Baldo, Helder F Teixeira
Frontiers in Genome Editing|July 24, 2023
Editorial: <i>Ex-vivo</i> and <i>in-vivo</i> genome engineering for metabolic and neurometabolic diseasesPasqualina Colella, Vasco Meneghini, Guilherme Baldo, et al.
Pageof 11